Fluad Tetra

DRUG4 trials

Sponsors

Seqirus UK Limited, Hipra Scientific S.L., Finnish Institute For Health And Welfare, Cr2o B.V.

Conditions

Avian influenza and seasonal influenzaCOVID-19 and fluInfluenza virusSARS-CoV-2 and Influenza

Phase 2

A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.

CompletedCTIS2023-506189-29-00

Hipra Scientific S.L.SARS-CoV-2 and Influenza

Start: 2023-09-04End: 2023-11-03Target: 300Updated: 2023-07-14

CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER

CompletedCTIS2024-514798-23-00

Cr2o B.V.COVID-19 and flu

Start: 2024-10-02End: 2025-03-04Target: 120Updated: 2024-10-14

Phase 3

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

RecruitingCTIS2022-503004-24-00

Seqirus UK LimitedInfluenza virus

Start: 2023-10-20Target: 27200Updated: 2025-12-10

Phase 4

Avian and seasonal influenza vaccine induced immune responses

RecruitingCTIS2023-509178-44-00

Finnish Institute For Health And WelfareAvian influenza and seasonal influenza

Start: 2024-06-26Target: 300Updated: 2026-01-21

Related Papers

Influenza A(H5N8) vaccine induces humoral and cell-mediated immunity against highly pathogenic avian influenza clade 2.3.4.4b A(H5N1) viruses in at-risk individuals.

2025-12-05